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INTRODUCTION
The development of levo-norgestrel implants 
(Norplant) was aimed at meeting the contraceptive 
need for a long-term reversible contraceptive free 
from estrogen side effects (1). Implant development 
began in 1966 with the pioneering research work 
of Segal and Croxatto (2,3). The development 
of subdermal contraceptive implants was made 
possible by the introduction of silicone rubber in 
the late 1940s. The original sub-dermal implants 
developed by the Population Council provided safe, 
convenient, reversible, long term and highly effective 
method of contraception for women (4). NorplantR 
is the trademark of the Population Council for levo-
norgestrel subdermal implants. The six-capsules 
system released approximately 30 mcg /day of 
levo-norgestrel, and was said to be effective for at 
least five years. Each capsule was about 34mm by 
2.4mm and contains 36 mg of free crystals of levo-
norgestrel. The continuation rates are good in many 
acceptors, and over half of the acceptors used the 
method by three years, while discontinuation rates 
were up to 14.1/100 users at four years (5). Medical 
reasons for the discontinuation included headaches, 
weight changes, and skin problems amongst others. 
Discontinuation prior to the recommended removal 
time of five years is likely to be among younger 
women desiring to be pregnant again. The return of 
fertility after removal is rapid and almost comparable 
to that of the normal population (5). About 76% of 
Norplant acceptors become pregnant 12 months after 
discontinuation, and 90% within 24 months (5). Pre-
introductory clinical trial in Nigeria was between 
1985 and 1990 (6,7), and Jos University Teaching 
Hospital participated in the trial. The implants were 
introduced into clinical settings in 1989, overlapping 
with the pre-clinical introductory clinical trial (6). 
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ABSTRACT
Objectives: To determine the acceptance of Norplant implants while it was in use and 
share our experience with other Norplant providers. 
Design: Retrospective descriptive study. 
Setting: The family planning clinic of the Jos University Teaching Hospital, Jos, 
Nigeria. 
Results: During the 21-year period, January 1985 to December 2005, a total of eighteen 
thousand, two hundred and ninety one (18,291) new clients accepted various modern 
contraceptive methods in the family planning clinic of Jos University Teaching Hospital, 
Nigeria. Norplant was accepted by 1,333 clients (4.9%) as against the intrauterine 
devices (IUDs) 25.4%, and Oral Contraceptive Pills (OCP) 22.9%. Female sterilisation 
was a contraceptive method of choice in 21.2%, the injectables in 13.9%, and the male 
condom in 9.3%. Failure rate was 0.37% and continuity rate was high among users. 
The Norplant contraceptive implant was accepted by women of mean age of 29.6 
years and women of all parity. The acceptance pattern demonstrated a multi-nodal 
pattern from the time of introduction in 1985 to December 2005 when supply came to 
an abrupt stop. The greatest barriers to Norplant use were non- availability and high 
cost of the commodity. 
Conclusion: Norplant implants provided contraceptive protection with high reliability, 
safety, independence from user compliance, rapid return of pre-existing fertility after 
removal, good tolerability, and relatively simple and quick insertion and removal. 
The capsules will definitely be used as a reference for similar contraceptive products 
in the contraceptive market. 
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Norplant got registered for use in Nigeria with 
National Agency for Food and Drug Administration 
and Control (NAFDAC), in 1998, with the registration 
number of 04-110 (8). 
 Jos University Teaching Hospital provides wide 
range of family planning methods. It commenced 
Norplant services to desiring clients in 1985 (9) but 
supply came to an abrupt end in November 2005 
following the stoppage of further manufacture and 
distribution of the contraceptive. Most women who 
have had Norplant liked it for its effectiveness, 
convenience and lack of serious complications (10), 
however few women had unacceptable problems 
warranting their removal before time. 
 The study was to determine Norplant acceptance 
compared with other methods, the trend, effectiveness, 
and side effects among the users during the period 
that it was in use. 
MATERIALS AND METHODS
This was a retrospective descriptive study aimed at 
sharing our experience of over two decades of use of the 
Norplant implant, a long term contraceptive method, 
in our Family Planning clinic setting. The period 
covered in the study was January 1985 to December 
2005; 21-year duration of use in the clinic. The records 
of all clients that used the implant and clients that used 
other modern methods of contraception were retrieved 
and analysed. The information extracted from the 
case notes of implant users included their age, parity, 
number of living children and weight at insertion. The 
duration of use of the implants, indication for removal, 
complications and side effects were also collated. The 
total yearly acceptance of Norplant and other methods 
of modern contraception accepted by clients were also 
computed from the register. 
RESULTS
A total of eighteen thousand, two hundred and ninety 
one (18,291) new clients accepted various modern 
contraceptive methods in the family planning clinic. 
Norplant was accepted by 1,333 clients (4.9%) as 
against the intrauterine devices (IUDs) 25.4%, and Oral 
Contraceptive Pills (OCP) 22.9%. Female sterilisation 
was a contraceptive method of choice in 21.2%, the 
Injectables in 13.9%, and the male condom in 9.3% 
cases. The acceptance of the method demonstrated 
a multiple modal pattern from introduction in 1985, 
until it came to an abrupt end in December 2005, 
Figure 1. The peak period of acceptance was between 
2003 and 2004, during which large consignment of 
the implants were received. 
Figure  1
The yearly distribution of Norplant acceptors, in 
percentages, compared with other modern contraceptive 
methods in Jos University Teaching Hospital between 
1985 and 2005 when supplies stopped
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 The socio-demographic parameters are as shown 
in Table 1. The clients were women of the reproductive 
age, with a mean age of33.2 ± 5.7 years. The women 
were of mean parity 3.8 ± 1.7 and about 31.5% were of 
parity five and above. Their mean weight at insertion 
was 66.6 ± 10.9 kg and the mean of the duration of 
use of the implants was 38.4 months. 
Table 1
Socio-demograpbic Characteristics of the Clients
  Range  Mean 
i.  Age of Women (years)  18 - 48  33.2 ± 5.7 
ii.  Weight (kg)  32 - 95  66.6 ± 10.9 
iii.  Parity  0 - 10  3.8 ± 1.7 
iv. Duration of use (months)  1 - 120  38.4 
 The common side effects were as seen in Table 
2. These included disruption of the menstrual cycle 
117 (62.9%), headaches 38 (20.4%), weight gain 22 
(11.9%) and infection of the insertion site in three 
(1.6%). Disruption of the menstrual cycle manifested 
as prolonged menstrual cycle 52, menorrhagia 17, 
spotting between periods 43 and amenorrhoea five. 
Table 2
Reported Side Effects experienced by Clients (n = 186*)
Reported Side Effect    No.  (%)   
i. Disruption of the menstrual cycle    117  (62.9)   
  -   Prolonged menstrual cycle    52   
  -   Spotting between periods    43   
  -   Menorrhagia    17   
  -   Amenorrhoea    5   
ii.  Headaches    38  (20.4)   
iii. Weight gain    22  (11.9)   
iv.  Infection    3  (1.6)   
v. Others  6  (3.2)   
(*Not all the side effects were indications for removal 
of the Norplant as many clients still kept the implants 
despite the side effects) 
 The most common indication for the removal of 
Norplant was the desire for another pregnancy (37.1 
%) and closely followed by expiration of the implants 
in the client’s arm (36.4%). Menstrual disruption 
constituted 13% of the indications for removal, Table 
3. Norplant was the most expensive of all available 
methods of contraception in the facility costing about 
twice the next costly method namely bilateral tubal 
ligation, Table 4. Norplant cost about N2,000 ($ 13) 
while bilateral tubal ligation cost N 1,000 ($ 7) . 
Table 3
Indications for Removal of Norplant Implants during 
Study Period
 Indication for removal  Number (%) 
i.  Desire for pregnancy  208 (37.1) 
ii. Expiration in vivo  204 (36.4) 
iii.  Menstrual disruption  73 (13.0) 
iv.  Headaches  22 (3.9) 
v.  Change to BTL  13 (2.3) 
vi.  Spousal disapproval  12 (2.1) 
vii.  Weight gain  7 (1.3) 
viii. Death of spouse  5 (0.9) 
ix.  Infection/partial expulsion  3 (0.5) 
x.  Others  13 (2.3) 
 Total  560 (100.0) 
Table 4
Comparative costs of the commonly used contraceptives 
in Jos
Contraceptive method Cost per Service in
 $US (Naira) 
Bilateral tubal ligation  7 (1,000) 
Injectables  0.5 (60) 
Intrauterine Devices  1.3 (200) 
Oral Pills  0.1 (15) 
Female Condom  0.1 (20) 
Male Condom  < 0.01 (1) 
Norplant  13 (2,000*)
($1 is equivalent to about 150 Naira; *Method 
therefore not affordable to many intending users of 
Norplant) 
DISCUSSION
Norplant implants were accepted by about 5% of 
clients using modern methods of contraception during 
the period of study. Norplant implants occupied the 
fifth position among other contraceptive methods 
in Jos and fourth place in Enugu (11). The relatively 
low acceptance was partly due to scarcity and cost 
of the implants (12); and the long term action of the 
implants for the clients. The cost of about $13 (N2,000) 
per set made it un-affordable to some clients desiring 
the use of Norplant. 
 Norplant was used by clients of all parity 
including the nullipara, to postpone a first pregnancy, 
or to ‘space’ pregnancies in those still desirous of 
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children; while yet in others to provide reversible, 
long-term contraception when the desired family 
size had been reached. 
 The implants required little or no motivation 
following adequate counselling (13,14). Continuation 
rates for implant use were high among those who 
had adequate pre-insertion counselling because 
the perceived advantages or benefits greatly 
outweighed the nuisance effects. One year following 
it is introduction, Norplant was found to be highly 
effective, safe and acceptable among Nigerian women 
of different ethnic groups. It was associated with 
a high degree of client satisfaction with a pooled 
continuation rate of 90.1 % after 12 months, 84.9% 
after 14 months and 77.1 % after 36 months (15). 
 The return of fertility after removal was rapid and 
almost comparable to that of the normal population. 
The failure rate was low and therefore found to be 
highly efficacious among our clients. Pregnancy 
occurred in five women out of 1,333 (0.37%). Two 
(2) additional women became pregnant at one year 
and 1.5 years after expiration of the capsules in situ, 
and not included in the cases of failure. Thus the 
method was adjudged to be very effective, preventing 
unwanted pregnancies in users. 
 The institution provided training in Norplant 
insertion and removal for about 200 service providers, 
namely Gynaecologists, Family Physicians, General 
Practice Doctors and Midwives. Norplant service 
provision was institutionalised in the department of 
Obstetrics and Gynaecology as all resident doctors in 
the department were trained to insert and remove the 
implant. Clients were provided the service between 
7.30 hours and 15.0 hours daily from Monday to 
Friday after adequate counselling. 
 The supply was epileptic to the centre thereby 
affecting the acceptance rate. The continuous use of 
Nor plant was hampered by inconsistent supply and 
availability of the commodity. The main barriers to 
Norplant use were therefore non-availability of the 
commodity between 1996 and 2001, and the high 
cost. Supplies totally depended on external sources 
and therefore affected availability and acceptance. 
Continuity of service was not guaranteed as the 
provision of the service stopped abruptly within the 
country in November 2005. 
 Inconsistent supply and availability of the 
commodity/capsules, interrupted supply, logistics, 
ready access, cost (capsules and consumables) and 
menstrual disturbances were the main draw backs 
to the use of Norplant during the period. The low 
incidence of subjective side effects experienced by 
Norplant users meant that it was safe. This was 
similar to the side effects of other progestogen-only 
contraceptives. The change in bleeding pattern during 
Norplant use was tolerated by clients as its acceptance 
was comparable to other progestogen-only methods. 
The Norplant implants had little impact on metabolic 
parameters (16). However, in the short term, there 
was a tendency to significant prolongation of ECG 
intervals in Norplant users (17). 
 Clinical as well as metabolic changes are known 
to be the attendant consequences of Norplant 
implants and steroidal contraception. The total serum 
triglycerides were found to be reduced in our clients 
using the implants (16). 
 Norplant provided five (5) years of contraceptive 
protection, high reliability, independence from user 
compliance, rapid return of pre-existing fertility after 
removal, good tolerability, and relatively simple and 
quick insertion and removal if the instructions for 
these were followed correctly (18-20). 
 As in many other parts of the country, Norplant 
was found to be safe and free from major side effects, 
effective, acceptable, suitable and reversible long 
acting progestin-only contraceptive method. The side 
effects were few, tolerable and menstrual changes 
were the most common side effect (21). Norplant 
definitely had a place in the prevention of unplanned 
and high risk pregnancies, one of the reproductive 
health elements of the millennium development goals 
(MDGs). 
 The continuation rate was high among users, and 
contributed a significant portion of the contraceptive 
armamentarium in Jos. The issue of availability 
however remained unresolved because of several 
factors such as logistics and high cost. These had 
serious inhibitory effects on the availability and hence 
the use/acceptance of the implants. While many 
workers recommended for Norplant to be made easily 
available, accessible and affordable to clients (18), it 
took about three years to get the implants from the 
manufacturers to the service delivery point, and two 
years to be used before expiration. 
 In conclusion, Norplant implants have come 
and gone, at least in Nigeria. Women that used 
this method of contraception found it useful and 
effective. Institutions found it an addition in their 
armentatarium of contraceptive methods. In its own 
way, it had a positive impact on the contraceptive 
arena. Few women found Norplant not very helpful 
and discontinued it is use within three months of 
insertion. Majority (89.0%) of the women used it for 
one term of about five years, while few used it for 
three terms of five years (15 years) in it is 21-year 
sojourn in Nigeria. 
 We anxiously look forward to ‘substitutes’, 
‘replacements’, ‘reliefs’, or ‘surrogates’, that will 
beat the record of this long acting progestin-only 
contraceptive implant that stood the test of time 
in a little over two decades of clinical use in our 
setting. The development of the one (Implanon) and 
two-rod (Jadelle) implant systems it is hoped would 
greatly simplify the insertion and removal of the 
contraceptive implants. Norplant has made it is mark 
as a method of contraception among many women 
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and will not be forgotten easily by those who used it. 
Norplant has left an indelible imprint or mark in the 
sands of contraceptive history. Norplant implant will 
definitely be used as a reference product for similar 
products in the contraceptive market. Norplant will 
also be remembered as an important, effective, and 
long-term contraceptive implant. Adieu Norplant, 
Adieu! 
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